Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02944448 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
A Phase 2 study, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 761
- Enrollment target
NCT02944448: Completed Phase 2 study, sponsored by Cara Therapeutics.
NCT02944448 is a Phase 2 study that has completed, run by Cara Therapeutics. The registered enrollment target is 761 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (472% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02944448, a Phase 2 study, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 761 participants
- Enrollment target
Study Summary
The study schedule consists of a Screening Period (up to 14 days), a blinded 4- week Titration-to-Effect Period with weekly visits, a blinded 4-week Maintenance Treatment Period at the optimal dose level determined for each patient, and a 1-week Follow-up Period. Eligible patients will be randomized to receive either CR845 or placebo in a 2:1 ratio. Every patient will be started on a 1-mg dose of CR845 or matching placebo. During the post-randomization Titration-to-Effect period, the dose of study drug may be increased to 2.5 mg or 5 mg in a double-blind fashion. Patients may know their dose is being changed but will not know whether they were randomization to active study drug or placebo. Approximately 330 patients will be enrolled in this study.
Primary Outcome
11-point NRS scale where 0 = no pain, and 10= pain as bad as you can imagine
Interventions
- DRUG Placebo tablet
- DRUG CR845 tablet 1 mg
- DRUG CR845 tablet 2.5 mg
- DRUG CR845 tablet 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 761 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
What the finished NCT02944448 record still lists
NCT02944448 is an interventional study that assigns participants to a tested intervention. The registered 761 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (472% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo tablet is the first listed.
NCT02944448 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02944448 about?
NCT02944448 is a clinical study titled "A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee". The study schedule consists of a Screening Period (up to 14 days), a blinded 4- week Titration-to-Effect Period with weekly visits, a blinded 4-week Maintenance Treatment Period at the optimal dose level determined for each patient, and a 1-week Follow-up Period. Eligible patients will be randomize...
What is the current status of trial NCT02944448?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 761 participants. The study started on 2016-09. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02944448?
The interventions under investigation include: Placebo tablet (DRUG), CR845 tablet 1 mg (DRUG), CR845 tablet 2.5 mg (DRUG), CR845 tablet 5 mg (DRUG).
Who is sponsoring clinical trial NCT02944448?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02944448's enrollment target sits among peer trials
761 43rd of 2000 higher than 1,958 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06419374 · 762 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- NCT02089607 · 760 participants · NA
CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft
- NCT04073706 · 760 participants · Phase 3
Sentinel Node Biopsy in Endometrial Cancer
- NCT05129228 · 760 participants · NA
Optical Coherence Tomography of the Saphenous Vein Graft
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia